Login to Your Account



Clinic Roundup


Friday, September 6, 2013
Civitas Therapeutics Inc., of Chelsea, Mass., initiated a Phase IIb study of CVT-301, an inhaled formulation of levodopa (L-dopa).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription